HPLC-MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-03. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
==== Antibiotics ==== In addition to established uses such as insulin administration, the subcutaneous route has increasingly been investigated for the delivery of selected antibiotics as an alternative to intravenous therapy in specific clinical contexts. Available pharmacokinetic and clinical evidence indicates that several time-dependent agents, including β-lactams (e.g. ceftriaxone) and glycopeptides (e.g. teicoplanin), can achieve systemic exposures comparable to intravenous administration while avoiding the need for venous access. This strategy may be particularly relevant for patients with difficult venous access, within outpatient parenteral antimicrobial therapy programs, and in palliative care settings; however, its use remains largely off-label and is supported primarily by observational studies and pharmacokinetic data.
== See also == Bonding in solids Bresle method (the method used to test for salt presence during coating applications) Carboxylate Halide Ioliomics Ionic bonds Natron Salinity Salt metathesis reaction
One of Proudhon's keenest students was the Russian revolutionary Mikhail Bakunin, who adopted his critiques of private property and government, as well as his views on the desirability of anarchy. During the Revolutions of 1848, Bakunin wrote of his hopes of igniting a revolutionary upheaval in the Russian Empire, writing to the German poet Georg Herwegh that "I do not fear anarchy, but desire it with all my heart". Although he still used the negative definition of anarchy as disorder, he nevertheless saw the need for "something different: passion and life and a new world, lawless and thereby free." Bakunin popularised "anarchy" as a term, using both its negative and positive definitions, in order to respectively describe the disorderly destruction of revolution and the construction of a new social order in the post-revolutionary society. Bakunin envisioned the creation of an "International Brotherhood", which could lead people through "the thick of popular anarchy" in a social revolution. Upon joining the IWA, in 1869, Bakunin drew up a programme for such a Brotherhood, in which he infused the word "anarchy" with a more positive connotation. He declared: "We do not fear anarchy, we invoke it. For we are convinced that anarchy, meaning the unrestricted manifestation of the liberated life of the people, must spring from liberty, equality, the new social order, and the force of the revolution itself against the reaction."
Sources: en.wikipedia.org
24296Cm + 42He → 24598Cf + 10n To identify and separate out the element, ion exchange and adsorption methods were undertaken. Only about 5,000 atoms of californium were produced in this experiment, and these atoms had a half-life of 44 minutes. The discoverers named the new element after the university and the state. This was a break from the convention used for elements 95 to 97, which drew inspiration from how the elements directly above them in the periodic table were named. However, the element directly above element 98 in the periodic table, dysprosium, has a name that means "hard to get at", so the researchers decided to set aside the informal naming convention. They added that "the best we can do is to point out [that] ... searchers a century ago found it difficult to get to California". Weighable amounts of californium were first produced by the irradiation of plutonium targets at Materials Testing Reactor at National Reactor Testing Station, eastern Idaho; these findings were reported in 1954. The high spontaneous fission rate of californium-252 was observed in these samples. The first experiment with californium in concentrated form occurred in 1958. The isotopes 249Cf to 252Cf were isolated that same year from a sample of plutonium-239 that had been irradiated with neutrons in a nuclear reactor for five years.
In metazoans, small interfering RNAs (siRNAs) processed by Dicer are incorporated into a complex known as the RNA-induced silencing complex or RISC. This complex contains an endonuclease that cleaves perfectly complementary messages to which the siRNA binds. The resulting mRNA fragments are then destroyed by exonucleases. siRNA is commonly used in laboratories to block the function of genes in cell culture. It is thought to be part of the innate immune system as a defense against double-stranded RNA viruses.
== Biography == Theodoros Angelopoulos was born in Athens on 27 April 1935. His father Spyros hailed from the town of Ampeliona, Messenia in the Peloponnese. During the Greek Civil War, his father was taken hostage and returned when Angelopoulos was 9 years old; according to the director, the absence of his father and looking for him among the dead bodies (during the "Dekemvriana" in Athens) had a great impact on his cinematography. He studied law at the University of Athens, but after his military service went to Paris to attend the Sorbonne. He soon dropped out to study film at the Institut des hautes études cinématographiques (IDHEC) before returning to Greece. There, he worked as a journalist and film critic. Angelopoulos began making films after the 1967 coup that began the Regime of the Colonels. He made his first short film in 1968 and in the 1970s he began making a series of political feature films about modern Greece: Days of '36 (Meres Tou 36, 1972), The Travelling Players (O Thiassos, 1975) and The Hunters (I Kynighoi, 1977). In 1978, he was a member of the jury at the 28th Berlin International Film Festival.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.